Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
| Enablex | Darifenacin hydrobromide | Bladder, overactive | Do not list | Complete | ||
| NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | ||
| Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | ||
| Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
| Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | ||
| Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete |
Last Updated : April 28, 2024